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Autoimmune hepatitis is a disease characterized by an elevation of liver enzymes, as well as speciﬁc autoantibodies. It is more
common in women than men. We describe a 32-year-old woman with elevated transaminases, autoantibodies, and a liver biopsy
result suggestive of autoimmune hepatitis. The indicated treatment was administered without showing a satisfactory response.
The patient had a family history of acute intermittent porphyria (AIP) so we decided to begin treatment with hematin, achieving
a complete remission of the symptoms. Acute intermittent porphyria is a rare condition characterized by neurovisceral symptoms,
abdominal pain being the most common of them. The disease has a higher prevalence among young women and certain European
countries such as Sweden, Great Britain, and Spain. A correct diagnosis and prompt treatment are essential because patients
aﬀected by AIP must have a strict followup due to the fatal outcome of the outbreaks.
1.Introduction
Acute intermittent porphyria (AIP, also known as Swedish
porphyria)isarareautosomaldominantinheritedmetabolic
disorder. The underlying cause is a deﬁciency in the por-
phobilinogen deaminase (PBG) enzyme, which is the third
enzyme in the heme biosynthesis pathway. The prevalence
of a mutant AIP gene may be as high as 1 per 500,
thus it shows an incomplete penetrance; the prevalence of
symptomatic disease is only 1-2 per 100,000, as stated by
Badminton and Elder [1]. This disease is more frequent
among young women. Although most individuals never
develop symptoms, the neurovisceral crises are the most
common presentation pattern in this type of porphyria,
abdominal pain being the most characteristic symptom.
Autoimmune hepatitis (AIH) is a chronic liver disease of
unknown etiology, characterized as periportal hepatitis with
hypergammaglobulinaemia and positive autoantibodies. It
can be prompted by environmental or inherent factors.
Antibodies to nuclei (ANA), smooth muscle (SMA), and
soluble liver antigen/liver pancreas (SLA/LP) characterize
type 1AIH. As discussed elsewhere, type 2AIH is associated
with antibodies to liver/kidney microsomes (ALKM-1) and
antibodies to liver cytosol antigen (ACL-1 or LC1) [2, 3].
The indicated treatment for AIH is steroids with or without
Azathioprine; this is typically well tolerable although some
patients need to switch the treatment to Cyclosporine or
Mycophenolate mofetil as published by Muratori et al. [4].
We describe a case of AIP, previously misdiagnosed as AIH,
in a patient with persistent elevation of liver enzymes.
A 32-year-old woman was referred to our hospital with a
diagnosis of AIH, with no clinically relevant background or
inﬂuence of any medication or alcohol use. She had persis-
tent elevation of transaminases (three times normal values),
gammaglobulines 18.8%, IgA 571mg/dL, IgG 1440mg/dL,
albumin51.5%,andalbumin/globulinratio0,95%,aswellas
anelevationofpositivesmoothmuscleantibodies(1/160and
1/80), and we excluded all other possible causes of hepatitis,
including viral markers (HBsAg and Anti-HCV), alpha 1
antitrypsin 136mg/dL, plasma iron 47μg/dL, and copper
157μg/dL. A liver biopsy was performed which denoted a
chronic hepatitis with moderate periportal activity, showing
lymphocyte inﬂitrates in the portal space that exceeds
the parenchimal stoma interphase. The hepatocytes were
arranged in a trabecular manner, and there was no evidence2 International Journal of Hepatology
Table 1
Initial situation After steroids and azatioprine After hematin
AST/ALT 81U/L/96U/L 85U/L/86U/L 34U/L/40U/L
GGT/FA 12U/L/177U/L 10U/L/165U/L 10U/L/122U/L
Gammaglobulines 18.8% 18.7% 17.7%
Ig A 571mg/dL 497mg/dL 331mg/dL
SMA 1/160 1/80 Negative
AST: aspartate aminotransferase, ALT: alanine aminotranferease, GGT: gamma glutamyl transferase, FA: alkaline phosphatase, and SMA: smooth muscle
antibodies.
of histologic alterations except for minor swelling. There
were also some ﬁbrous porto-portal tracts. The revised
Original Scoring System of the International Autoimmune
Hepatitis Group was applied, reaching a score of 15 points,
whichmakesitaprobablediagnosisofautoimmunehepatitis
as reported by Manns et al. [5]
We started her on Prednisone 1mg/kg, and Azathioprine
50mgperday,increasingitto150mgperday;however,there
was no response to the treatment, and the liver enzymes
remained elevated by three times the normal value (see
Table 1). The only signiﬁcant aspect of the medical history
was that three out of her ﬁve sisters had been diagnosed
with AIP. Following this information, we tested for AIP,
and the laboratory results showed urine coproporohyrin
433μg/day (normal range 50–200μg/day) and uroporphyrin
173μg/day (normal range 5–70μg/day). Erythrocyte deam-
inase PBG enzymatic activity was 42U/LH (normal range
85–160U/LH). Urine porphobilinogen (12mg/day) and δ-
aminolaevulinic acid (7.4mg/day) were slightly increased, as
well as a sharply deﬁned plasma ﬂuorescence emission of
619nm. Therefore, the diagnosis of AIP was established.
We began treatment with 250mg daily for four days of
hematin (NORMOSANG), following a monthly dose, along
with a gradual reduction of the steroids until suspension.
Newlaboratorytestswereperformedtwomonthslaterwhich
included hemogram, basic and liver proﬁles, cholesterol,
triglycerides, TSH, coagulation, antinuclear, antimitochon-
drial, anti-ALKM, anti-SMA, and celiac disease antibodies,
proteinogram, and immunoglobulins. All test results showed
values within normal limits, except for the following: ALT
40UI/l, seroalbumins 56.1%, alpha 2 globulins 10.3%, beta
globulins 12.4%, and total proteins 6.9g/dL.
The available data makes the diagnosis of autoimmune
hepatitis unlikely, mostly because of the response obtained
when the new treatment was established. The patient was
reevaluated for the following years and remained asymp-
tomatic, without presenting abdominal pain or dark urine,
and having normal menstrual periods and laboratory test
values.
2. Discussion
The coexistence of AIP and AIH is extremely rare; they do,
however, share a chronic elevation of transaminases. This
association has not yet been described. We have conducted
a thorough research through the literature looking for such
association but were unable to ﬁnd a link. Because of this, we
conclude that the resolution of this case report has shown
that the ﬁnal diagnosis was acute intermittent porphyria,
expressed as an elevation of transaminases, and was initially
misdiagnosed as AIH, a situation that could have led the
patient to an increase in both morbidity and mortality. As
reported by Ohtani et al., there have been reports of acute
intermittent porphyria causing a mild increase of the liver
enzymesandothersthatreportanelevationoftransaminases
associated with abdominal pain [6, 7]. With this knowledge,
it is imperative to denote that an early diagnosis of AIP
is crucial because acute porphyries can be life threatening,
and, of all of them, AIP is considered to be the most
severe. As presented by Raigal, a 50% reduction of the
activity of the PBG deaminase is suﬃcient to appreciate
clinical manifestations [8]. As suggested elsewhere, it is
also important to keep in mind all the known triggering
factors, such as medication drugs, changes in women’s
hormonal cycles, caloric deprivation, tobacco, alcohol, or
infections [9]. These factors can cause the accumulation
of delta aminolevulinic acid (ALA) and PBG—which are
normally eliminated through urine and feces—in the tissues,
producing the clinical symptoms. AIPs treatment is based on
avoidance of the attacks. During an acute attack, intravenous
carbohydrates(400gperday)shouldbeadministered,aswell
as hematin 3–5mg per kg for at least 4 days as stated by
Raigal et al. [8]. In order to have a better understanding of
the possible association between both diseases, more studies
have to be performed.
In conclusion, young women with chronic elevation
of transaminases of unexplained etiology and unspeciﬁc
liver biopsy should be evaluated for AIP especially if they
also present intense and recurrent abdominal pain and
dysautonomy, as the possibility of such a diagnosis is latent.
Also, periodic screening of alpha-fetoprotein should be
performed in patients with AIP and chronic elevation of
liver enzymes since they have greater risk of developing
hepatocarcinoma.
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